Danaher expects Q3 2026 non-GAAP core revenue growth of 2.0% to 3.0% year-over-year
Company raises full-year 2026 adjusted diluted EPS guidance to $8.45-$8.60
Danaher expects full-year 2026 non-GAAP core revenue growth of 3.0% to 4.0% year-over-year
Overview
US life sciences and diagnostics firm's Q2 revenue rose, beating analyst expectations
Adjusted EPS for Q2 grew 8% and beat analyst expectations
Company raised full-year adjusted EPS guidance after strong Q2 and Masimo acquisition
Result drivers
Life sciences strength - Life Sciences segment delivered its strongest quarter in several years, per CEO Rainer M. Blair
Bioprocessing orders - Bioprocessing revenue was impacted by customer project timing, but orders grew mid-teens and underlying trends remained strong, per CEO
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Danaher Corp is $237.50, about 18.1% above its July 20 closing price of $201.11
The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 22 three months ago
DHR•
